Supplementary Material for: Evaluation of the First-dose Anti-VEGF Anatomical Response in Polypoidal Choroidal Vasculopathy Patients: Correlation with the Third-dose Response and Risk Factors Analysis
Yan Wang(National Institute of Biological Sciences, Beijing), On behalf of the China PCV Research Alliance Study Group, X.-C. Zhang(Beijing Institute of Technology), Weidong Zhang(Hangzhou Hospital of Traditional Chinese Medicine), Yi Chen, Xiaoying Zhao(Handan College), Jin‐Ji Yang(Guangdong General Hospital), Meng Lv(Nanfang Hospital)
Cited by 0
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743